Skip to content
Menu

Scinai Immunotherapeutics Ltd. SCNI

Full chart Compare
Set alert

Price alert · SCNI

All alert types
0.40 USD 0.00 (+1.02%)

Regular-session close

0.40 0.00 +0.02%

After hours · Nov 16, 4:00 PM ET

0.3898 Day range 0.4269
0.387 52-week range 13.00
YTD
-94.32%
1 year
-95.87%
Market cap
1.06M
Revenue (ttm)
284.00K
EPS (ttm)
3.30
Shares out
853.00K
P/E ratio
0.12
YTD return
-94.32%
1-year return
-95.87%
Volume
27.21K
Avg volume
2.16M
Open
0.3898
Previous close
0.40
Day's range
0.3898 – 0.4269
52-week range
0.387 – 13.00
Beta
2.46

5D -0.0416 (-9.42%)

0.40000.45000.50000.5500MonTueWedThuFri0.4000

Key statistics

50-day average
3.41
200-day average
3.91
Enterprise value
10.13B
Price / sales
10.06
Free cash flow
-3.79M
Total cash
3.08M
Total debt
20.82M
Short % of float
0.88%

Fundamental scorecard

3 of 25 checks passed on SCNI’s reported financials

ValueGrowthProfitabilityHealthDividend

3of 25 checks passed

  • Value 1 of 5
  • Growth 0 of 5
  • Profitability 0 of 5
  • Financial health 2 of 5
  • Dividend No data

Statements to Sep 30, 2026.

Financials — quick view

All financials
SCNI Revenue — quarterly 1.86M
SCNI Net income — quarterly -1.97M
SCNI EPS — quarterly -104.00

Earnings

SCNI recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 22, 2024Sep 1, 20240.008.40——
Aug 15, 2024Jun 1, 20240.00-3.57——
Jul 2, 2024Mar 1, 20240.00-4.00——
May 15, 2024Dec 1, 20230.00-240.00——
Oct 31, 2023Sep 1, 20230.00-6.60——

About Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel
Website
scinai.com

News

Your note

Sign in to keep a note on SCNI — it syncs with the Stock Master app.

Institution ownership

SCNI institution ownership
Holder% heldSharesValueReported
Rhumbline Advisers0.19%1,6535.54KSep 29, 2024
Morgan Stanley0.03%255854Sep 29, 2024
Aspire Private Capital, LLC0.00%32107Sep 29, 2024
Credit Agricole S.A.0.00%42140Sep 29, 2024
UBS Group AG0.00%30100Sep 29, 2024

Fund ownership

SCNI fund ownership
Holder% heldSharesValueReported
SPDR Portfolio Developed World ex-US ETF0.00%26Sep 29, 2024